Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.80 |
| ▸ | FYN | P06241 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | BLK | P51451 | 1/20 | 0.71 |
| ▸ | BMX | P51813 | 1/20 | 0.71 |
| ▸ | JAK3 | P52333 | 1/20 | 0.71 |
| ▸ | BTK | Q06187 | 1/20 | 0.71 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378352 | 1.00 | EGFR (0.80) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL16882294 | 0.90 | EGFR (0.82) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL30115309 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1418064 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL1418066 | 0.89 | EGFR (0.81) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL5374126 | 0.89 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL5374128 | 0.89 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL30115339 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL867889 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK | |
| SCHEMBL867890 | 0.89 | EGFR (1.00) | EGFRERBB2FYNSRCBLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | disclosed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ERBB2 2/4885FYN 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.